Marker Progression and Sample Sizes Estimates for Trials in Prodromal Parkinson’s Disease: A Multicenter Study
Objective: To inform the design of randomized neuroprotective trials in prodromal Parkinson’s disease (PD) by assessing the progression of prodromal markers in idiopathic rapid eye…Relationship between cardiovascular autonomic failure and cognitive performance in the α-synucleinopathies: preliminary cross-sectional analysis of the NHSS registry
Objective: To compare cognitive performances of patients with α-synucleinopathies with or without cardiovascular dysautonomia. Background: Cardiovascular dysautonomia is a disabling non-motor feature of the α-synucleinopathies and may…in vivo and autopsy validation of alpha-synuclein seeding activity using RT-QuIC assay in the gastrointestinal tract of patients with Parkinson’s disease
Objective: To evaluate pathologic alpha-synuclein (AS) seeding activity with Real-time quaking-induced conversion (RT-QuIC) assay using formalin fixed paraffine-embedded (FFPE) tissue of GI tract in Parkinson's disease (PD)…Dopamine neuron platform for screening molecular mechanisms and inhibitory drugs against alpha-synuclein aggregation
Objective: Optimization of a dopamine neuron based,in vitro platform is beneficial for studying molecular mechanisms of alpha-synuclein aggregation,and screening of inhibitory drugs and deducing their…Development and validation of clinical scales for defining RBD severity in participants of the North American Prodromal Synucleinopathy (NAPS) consortium
Objective: The objective of this study is to assess the internal validity of the REM Sleep Behavior Disorder (RBD) symptom severity scale (RBDSSS) and its…A clinico-genetic study based on the Innsbruck MSA Registry
Objective: To assess family history (FH) for neurodegenerative disorders in people with multiple system atrophy (MSA), compare its prevalence with that of a prospectively recruited…Microglial activation facilitates alpha synuclein propagation and neurodegeneration in αSyn preformed fibrils (PFF)-injected PD mouse model
Objective: To evaluate whether microglial activation aggravates synucleinopathy progression in Parkinson's disease (PD) mouse model. Background: Alpha-synuclein (αSyn) accumulation underlay the main pathological process of…Central olfactory structure atrophy is linked to synucleinopathy conversion in idiopathic REM sleep behavior disorder
Objective: We hypothesized that early structural changes in the brain olfactory relevant structures may help early identification of those at risk of future disease conversion…Addressing pathological alpha-synuclein aggregation using a small molecule strategy
Objective: The discovery of cell-permeable, orally bioavailable and brain penetrant small molecules with the potential of inhibiting aggregation and intracellular accumulation of pathological alpha-synuclein (a-syn)…Development of C-terminal α-Synuclein Vaccine for Treatment and Prevention of Parkinson’s Disease and Other Synucleinopathies
Objective: Prothena is developing active vaccine candidates targeting α-synuclein (α-syn) epitopes shown in clinical and/or preclinical studies to disrupt synuclein pathology. These vaccines, which target…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 17
- Next Page »